

References

- **Aboulghar MA and Mansour RT (2003)** Ovarian hyperstimulation syndrome: classifications and critical analysis of preventive measures. Hum Reprod Update 9,275-289.
- **Aboulghar MA, Mansour RT, Serour GI, Al-Inany HG, Amin YM and Aboulghar MM (2004)** Increasing the dose of human menopausal gonadotropins on day of GnRH antagonist administration: randomized controlled trial. Reprod Biomed Online 8,524-527.
- **Acharya U., Irvine D.S., Hamilton M.P.R and Templeton A.A.** The effect of three anti-oestrogen drugs on cervical mucus quality and in-vitro sperm cervical mucus interaction in ovulatory women Human Reproduction, Vol. 8, No. 3, pp. 437-441, **1993**.
- **Ákos Murber , Péter Fancsovits, Nóra Ledó, Zsuzsa Tóthné Gilán, János Rigó Jr and János Urbancsek** Impact of GnRH analogues on oocyte/embryo quality and embryo development in vitro fertilization/intracytoplasmic sperm injection cycles: a case control study., Reproductive Biology and Endocrinology **2009**, 7:103 doi:10.1186/1477-7827-7-103.
- **Al. Fozan H, AL-Khadury M. Tan SL., Tulandi T. (2004):** A randomized trial of Letrozole versus clomiphene citrate in women undergoing superovulation. Fertil Steril 82: 1561-3.
- **Albano C, Felberbaum RE, Smitz J, Riethmüller-Winzen H, Engel J, Diedrich K,** et al. Ovarian stimulation with hMG: results of prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LH-RH) antagonist Cetrorelix and the LH-RH agonist buserelin. Hum Reprod **2000**; 15:526–31.
- **Albano C, Grimbizis G, Smitz J, Riethmüller-Winzen H, Reissmann T, Van Steirteghem A and Devroey P (1998)** The luteal phase of nonsupplemented cycles after ovarian superovulation with human menopausal gonadotropin and the gonadotropin-releasing hormone antagonist Cetrorelix. Fertil Steril 70,357-359.

References

- **Albano C, Smitz J, Camus M, Bennink HC, Van Steirteghem AC, Devroey P (1996):** Pregnancy and birth in an in-vitro fertilization cycle after controlled ovarian stimulation in a woman with a history of allergic reaction to human menopausal gonadotropin. *Hum Reprod* 11:1632-1634.
- **Albano C, Smitz J, Camus M, Riethmuller-Winzen H, Van Steirteghem A and Devroey P (1997)** Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation. *Fertil Steril* 67,917-922.
- **Al-Inany HG, Aboulghar M, Mansour R and Serour GI (2005)** Optimizing GnRH antagonist administration: meta-analysis of fixed vs flexible proto-col. *Reprod Biomed Online* 10,567-570.
- **Al-Inany HG, Abou-Setta AM, Aboulghar M** .gonadotropin releasing hormone antagonists for assisted conception. *Cochrane Database Syst Rev* 2006;3:CD001750.
- **Al-Inany H., and Aboulghar M.** GnRH antagonist in assisted reproduction: Cochrane review. *Hum Reprod.* 2002; 17: 874-85.
- **Alstair, S. (2001).** Intracytoplasmic sperm injection and other aspects of new reproductive technologies. Retrieved from Leading articles: www.archdischild.com.
- **American society for reproductive medicine (2001):**Intra cytoplasmic sperm injection fact sheet 03-16-06.
- **Andersen AN, Goossens V, Gianaroli L, Felberbaum R, de MJ, Nygren KG. Assisted reproductive technology in Europe, 2003.** Results generated from European registers by ESHRE. *Hum Reprod* 2007;22(6):1513–1525. [PubMed: 17470881].
- **Andre CD, Van Loenen M.D, Judith A.F, et al (2002):** GnRH agonists and antagonists and assisted reproduction, seminars in reproductive medicine volume 20, number 4 ,349-358.
- **Anik ST, McRae G, Nerenberg C et al (1984):** Nasal absorption of nafarelin acetate, the decapeptide [D-Nal 6)] LHRH, in rhesus monkeys *I.J Pharm Sci*;73:684-685.

References

- **Arce JC, Nyboe Andersen A and Collins J (2005)** Resolving methodological and clinical issues in the design of efficacy trials in assisted reproductive technologies: a mini-review. *Hum Reprod* 20,1757-1771.
- **Ascheim S, Zondek B (1927):** Hypophysen vorderlappen hormone and ovarian hormone in Harn von Schangeren. *Klin Wochenschr* 6:13-21.
- **Ashkenazi J, Goldman JA , Kicker K, et al.(1990).** Adverse neurological symptoms after gonadotrophin-releasing hormone analog therapy for in vitro fertilization cycles. *Fertil Steril* 1990; 53: 738-740.
- **Balach J, Penarrubia J, Fabregues F, et al (1994).** Human chorionic gonadotrophin luteal support overcome luteal phase inadequacy of gonadotrophin releasing hormone agonist induced ovulation gonadotrophin stimulated cycles. *Hum Reprod* vol.13, no12, pp 3315-3318. (1998).
- **Balen A, Tan SL , MacDougall MJ, et al.(1992):** Miscarriage rates following in vitro fertilization are increased in women with polycystic ovaries and reduced by pituitary desensitization with buserelin. *Hum Reprod* 1992; 8: 959-64.
- **Balen AH, Hayden CJ, Rutherford AJ (1999):** What are the clinical benefits of recombinant gonadotrophins?. Clinical efficacy of recombinant gonadotropins. *Hum Reprod* 14:141 1-1417.
- **Balen H, And Jacobs S, (2003)** Infertility in practice, section 4 complications of ovulation stimulation, 389-410 Churchill Livingstone, 2nd edition.
- **Barmat LI, Chantilis SJ, Hurst BS, Dickey RP:** A randomized prospective trial comparing gonadotropin-releasing hormone (GnRH) antagonist/recombinant follicle-stimulating hormone (rFSH) versus GnRH-agonist/rFSH in women pretreated with oral contraceptives before in vitro fertilization. *Fertil Steril* 2005, 83(2):321-330.
- **Bassil S (2001):** Changes in endometrial thickness. Width Length and pattern in predicting pregnancy outcome during ovarian stimulation in in vitro fertilization. *Ultrasound Obstet Gynecol* 18:258.

- **Bayalos RP and Lee CT (1996):** Polycystic ovary syndrome pathophysiology and outcome with in vitro fertilization, *Fertil Steril* 65: 1-10.
- **Beckers NG, Macklon NS, Eijkemans MJ, Ludwig M, Felberbaum RE, Diedrich K, Bustion S, Loumaye E and Fauser BC (2003)** Nonsupple-mented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment. *J Clin Endocrinol Metab* 88,4186-4192.
- **Bendikson K, Milki A, Speck-Zulak A and Westphal L (2003)** Comparison of GnRH antagonist cycles with and without oral contraceptive pill pretreatment in poor responders. *Fertil Steril* 80(Suppl. 3), s188.
- **Bergh C, Werner C, Nilsson L, Hamberger L.** Cumulative birth rates following cryopreservation of all embryos in stimulated in vitro fertilization (IVF) cycles. *J Assist Reprod Genet* **1995**;12:191 – 194.
- **Bonduelle M, Ponjaert I, Steirteghem AV, Derde MP, Devroey P, Liebaers I.** Developmental outcome at 2 years of age for children born after ICSI compared with children born after IVF. *Hum Reprod* Feb;**2003** 18(2):342–350. [PubMed: 12571172].
- **Bonduelle M, Wennerholm UB, Loft A, et al.** A multi-centre cohort study of the physical health of 5- year-old children conceived after intracytoplasmic sperm injection, in vitro fertilization and natural conception. *Hum Reprod* Feb;**2005** 20(2):413–419. [PubMed: 15576393].
- **Borm G, Mannaerts B.** Treatment with the gonadotropin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group. *Hum Reprod* **2000**;15:1490–8.

References

- **Bouloux P.M, Handelsman DJ, Jockenhovel F, et al. (2001):** First human exposure to FSH-CTP in hypogonadotrophic hypogonadal males. *Hum Reprod* 16:1592-1597.
- **Branigan FF, Estes MA (2000):** Minimal stimulation IVF using clomiphene citrate and oral contraceptive pill pretreatment for LH suppression. *Fertil Steril* 73:587.
- **Broekmans FJ, Bernardus RE, Berkhout G, Schoemaker J. (1992):** Pituitary and ovarian suppression after early follicular and mid-luteal administration of a LHRH agonist in a depot formulation: decapeptyl CR. *Gynecol Endocrinol*;6:153-161.
- **Brown RM (1994).** An introduction to Neuroendocrinology. Cambridge, UK: Cambridge University Press. ISBN 0-521-42665-0.
- **Buck Louis GM, Schisterman EF, Dukic VM, Schieve LA.** Research hurdles complicating the analysis of infertility treatment and child health. *Hum Reprod* Jan;2005 20(1):12–18. [PubMed: 15489239].
- **Caglar G, Asimkopoulos B, Nikolettos N, Diedrich K, Al_hasani S(2005)** “RECOMBINANT LH IN OVARIAN STIMULATION”. Reported biomed online 10 (6):774-85. PMID 15970010.
- **Campbell RE, Gaidamaka G, Han SK, Herbison AE (June 2009).** "Dendro-dendritic bundling and shared synapses between gonadotropin-releasing hormone neurons". *Proc. Natl. Acad. Sci. U.S.A.*. doi:10.1073/pnas.0903463106. PMID 19541658.
- **Cann Ce, Henzl M. and Burry K (1987):** Reversible bone loss is produced by the GnRH agonist nafarelin, in Cohn Cv, Martin Th ,Meunier Ph(eds): *Calcium Regulation and Bone Metabolism, Basic and Clinical Aspects*. Vol .9. Amsterdam Excerpta Medica. pp 123-127.
- **Cedrin-Durnerin I, Grange-Dujardin D, Laffy A, Parneix I, Massin N, Galey J, Theron L, Wolf JP, Conord C, Clement P et al. (2004)** Recombinant human LH supplementation during GnRH antagonist administration in IVF/ICSI cycles: a prospective randomized study. *Hum Reprod* 19,1979-1984.

References

- **Centers for Disease Control and Prevention (2006).** Assisted Reproductive Technology (ART) Report: 2005 Preliminary Clinic Data by State and National Summary. Available online:
- **Chappel and howles c.(1991):** re_evaluation of the role of lutinizing hormones and follicle_stimulating hormones in the ovulatory process: untimately surges of lh . HUM. Repod 6:1206_1212.
- **Chen TH, Chang SP, Tsai CF, Juang KD:** Prevalence of depressive and anxiety disorders in an assisted reproductive technique clinic. Hum Reprod **2004**, 19:2313-2318.
- **Cheng CK and Leung PCK (2005)** Molecular biology of gonadotropin-releasing hormone (GnRH)-1, GnRH-II, and their receptors in humans. Endocr Rev 26,283-306.
- **Cheung LP, Lam PM, Lok IH, Chiu TT, Yeung SY, Tjer CC and Haines CJ (2005)** GnRH antagonist versus long GnRH agonist protocol in poor responders undergoing IVF: a randomized controlled trial. Hum Reprod 20,616-621.
- **Conn PM, Crowley WF Jr:** Gonadotropin-releasing hormone and its analogs. Annu Rev Med **1994**, 45:391-405.
- **Corson SL, Batzer FR, Gocial B, et al. (1993):** The luteal phase after ovulation with human menopausal gonadotropin and one versus two dose of a gonadotropin releasing hormone agonists. Fertil. Steril. 1993; 59: 1251-1256.
- **Damewood MD, SchlafT WD , Hesla JS, et al (1989):** Interval bone mineral density with long-term gonadotropin-relcasing hormone agonist suppression: Fertil Steril 1989;52:596-9.
- **Daya S.** Gonadotropin releasing hormone agonist protocols for pituitary desensitization in in vitro fertilization and gamete intrafallopian transfer cycles. Cochrane Database Syst Rev **2000**;CD001299 (The Cochrane Collaboration issue 2, Oxford).
- **De Jong D, Macklon NS and Fauser BC (2000)** A pilot study involving minimal ovarian stimulation for in vitro fertilization: extending the 'follicle-stimulating hormone window' combined with the gonadotropin-releasing hormone antagonist cetorelix. Fertil Steril 73,1051-1054.

- **De Neubourg DD, Mangelschots K, Van Royen E, Vercruyssen M, Ryckaert G, Valkenburg M, Barudy-Vasquez J, Gerris J.** Impact of patients' choice for single embryo transfer of a top quality embryo versus double transfer in the first IVF/ICSI cycle. *Hum Reprod* **2002**;17:2621 – 2625.
- **De Sutter, P., Dozortsev, D., Qian, C. et al (1996)** Oocyte morphology does not correlate with fertilization rate and embryo quality after intracytoplasmic sperm injection. *Hum. Reprod.*, 11, 595-597.
- **DelGadillo JC, Siebzehnruhl J, Diedrich R, et al.** Comparison of GnRH agonists and antagonists in unselected IVF/ICSI patients treated with different controlled ovarian hyperstimulation protocols: a matched study. *European J. of Obstet/Gynecol and Reprod. Biol.* **2002**; 102:179-183.
- **Delvigne A and Rozenberg S (2002)** Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. *Hum Reprod Update* 8,559-577.
- **Devogelaer JP, Nagant de Deuxchaisnes C, Donnez J, et al (1987):** LHRH analogues and bone loss. *Lancet* 1: 1498.
- **Devreker F, Govaerts I, Bertrand E, et al (1996):** The long acting gonadotropin releasing hormone analogues impaired the implantation rate. *Fertil Steril*; 65:122-126.
- **Devroey P, Bourgain C, Macklon NS, Fauser BC (2004):** Reproductive biology and IVF: ovarian stimulation and endometrial receptivity. *Trends Endocrinol Metab* 15:84 -90.
- **Devroey P, Van Steirteghem A, Mannaerts B, Coelingh BH (1992):** First singleton term birth after ovarian superovulation with rhFSH. *Lancet* 340:1108- 1109.
- **Devroy P, GnRH antagonist, Fertil. Steril. 73 (2000), pp. 15-17.**
- **Dickey RP. Holtkamp DE (1996):** Development Pharmacology and clinical experience with clomiphene citrate. *Hum Reprod Update* 2:483.

- **Diedrich K, Diedrich C, Santos E, Zoll C, al-Hasani S, Reissmann T, Krebs D and Klingmuller D (1994)** Suppression of the endogenous luteinizing hormone surge by the gonadotropin-releasing hormone antagonist Cetrorelix during ovarian stimulation. *Hum Reprod* 9,788-791.
- **Dlugi A, Miller JD, Knittle J, et al (1990):** Lupron depot in treatment of endometriosis: A randomized placebo controlled double blind study. *Fertil Steril*;54:419.
- **Dodin S, Lemay A, Maheux R, et al (1991):** Bone mass in endometriosis patients treated with GnRH agonist implant of danazol. *Obstet Gynecol* 1991;77: 410-415.
- **Donderwinkel PF, Schoot DC, Coelingh Bennink HJ, Fauser BC (1992):** Pregnancy after induction of ovulation with recombinant human FSH in polycystic ovary syndrome. *Lancet* 340:983.
- **Dorrington J H, and Armstrong DT.** Effects of FSH on gonadal function. *Rec prog Horm Res.* **1979**; 39:301.
- **Driancourt MA, Gougeon A, Royere D and Thibault C. (1991)** Inlareproduction chez les mammifères etc, home, edited by C. Thibault and M.C. Levasseur. Pp273_298. Ellipses INRA. Edition Marketing. Paris.
- **Duijkers IJ, Klipping C, Boerrigter PJ, Machielsen CS, de Bie J J, Voortman G (2002):** Single dose pharmacokinetics and effects on follicular growth and serum hormones of a long-acting recombinant FSH preparation (FSH-CTP) in healthy pituitary-suppressed females. *Hum Reprod* 17:1987-1993.
- **Dungan HM, Clifton DK, Steiner RA (March 2006).** "Minireview: kisspeptin neurons as central processors in the regulation of gonadotropin-releasing hormone secretion". *Endocrinology* 147 (3): 1154–8. doi:10.1210/en.2005-1282. PMID 16373418.
- **Edwards RG, Lobo R, Bouchard P:** Time to revolutionize ovarian stimulation. *Hum Reprod* **1996**, 11(5):917-919.

- **Elizur SE, Aslan D, Shulman A, Weisz B, Bider D and Dor J (2005)** Modified natural cycle using GnRH antagonist can be an optional treatment in poor responders undergoing IVF. *J Assist Reprod Genet* 22,75-79.
- **Engel JB, Riethmuller-Winzen H and Diedrich K (2005)** Extrapituitary effects of GnRH antagonists in assisted reproduction: a review. *Reprod Biomed Online* 10,230-234.
- **Erickson GF.** Follicular maturation and atresia :flamignic, Givens, J.R., (eds). the gonadotropins: basic science and clinical aspects in females. Academic, New York. **1982**; pp: 171-86.
- **Escudero E, Bosch E, Crespo J, Simon C, Remohi J and Pellicer A (2004)** Comparison of two different starting multiple dose gonadotropin-releasing hormone antagonist protocols in a selected group of in vitro fertilization-embryo transfer patients. *Fertil Steril* 81,562-566.
- **ESHRE.** The European IVF monitoring programme (EIM), for the European Society of Human Reproduction and Embryology. Assisted reproductive technology in Europe, 2004. Results generated from European registers by ESHRE. *Hum Reprod* **2008**;23:756–771.
- **Fanchin R. Righini C, Ayoubi JM, et al. (2000):** New look at endometrial. echogenicity: objective computer-assisted measurements predict endometrial receptivity in in vitro fertilization-embryo transfer. *Fertil Steril* 74:274.
- **Fares FA, Suganuma N. Nishimori K, LaPolt PS, Hsueh AJ, Boime I (1992):** Design of a long-acting follitropin agonist by fusing the C terminal sequence of the chorionic gonadotropin subunit to the follitropin subunit, *Proc Natl Acad Sci USA* 89:4304-4308.
- **Farish E, Fletcher CD , Barnes JF, et al.(1992):**Reversible menopause induced by the GnRH analogue buserelin: effects on lipoprotein metabolism. *Acta Endocrinol (Copenh)* 127: 123-6.
- **Fassino S, Piero A, Boggio S, Piccioni V, Garzaro L:** Anxiety, depression and anger suppression in infertile couples. *Hum Reprod* **2002**, 17:2986-2994.

- **Fauser BC (1998):** Developments in human recombinant follicle stimulating hormone technology: are we going in the right direction? *Hum Reprod* 13(Suppl 3): 36-16.
- **Fauser BC and Devroey P (2005)** Why is the clinical acceptance of gonadotropin-releasing hormone antagonist co-treatment during ovarian hyperstimulation for in vitro fertilization so slow? *Fertil Steril* 83,1607-1611.
- **Fauser BC and Van Heusden AM (1997)** Manipulation of human ovarian function: physiological concepts and clinical consequences. *Endocr Rev* 18,71-106.
- **Fauser BC, de Jong D, Olivennes F, Wramsby H, Tay C, Itskovitz-Eldor J and van Hooren HG (2002)** Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization. *J Clin Endocrinol Metab* 87,709-715.
- **Fauser BC, Devroey P and Macklon NS (2004)** Multiple birth resulting from ovarian stimulation for subfertility treatment. *Lancet* 365,1807-1816. Felberbaum RE and Diedrich K (2003) Gonadotropin-releasing hormone antagonists: will they replace the agonists? *Reprod Biomed Online* 6,43-53.
- **Fauser BC, Macklon NS (2004):** Medical approaches to ovarian stimulation for infertility. In: Strauss JF. Barbieri RL. eds. Yen and Jaffe's reproductive endocrinology. Philadelphia: Elsevier Saunders; 965-1012.
- **Felberbaum R and Diedrich K (2000):** Ovarian stimulation of invitro fertilization and intracytoplasmic sperm injection with gonadotrophins and gonadotrophin-releasing hormone analogues: agonists and antagonists. *Hum Reprod*; 14 (suppl.1):2072.
- **Felberbaum R, Reissmann T, Zoll C, Kupker W, al-Hasani S, Diedrich C, Diedrich K:** [GnRH antagonists in gynecology: initial results within the scope of controlled ovarian hyperstimulation]. *Gynakol Geburtshilfliche Rundsch* 1995a, 35(Suppl 1):113-117.
- **Felberbaum RE, Reissmann T, Kupker W, Bauer O, al Hasani S, Diedrich C and Diedrich K (1995b)** Preserved pituitary response under ovarian stimulation with HMG and GnRH antagonists (Cetrorelix) in women with tubal infertility. *Eur J Obstet Gynecol Reprod Biol* 61,151-155.

- **Fischl F, Huber JC, Obruca A (2001)** Zeitliche optimierung der kontrollierten hyperstimulation (koh) in kombination mit gnrh-antagonisten und ovulationshemmer in einem ivf-programm. J Fertilitat Reproduktion 11,50-51.
- **Fisher SA, Reid RL, Van Vugt DA, Casper RF (2002):** A randomized double-blind comparison of the effects of clomiphene citrate and the aromatase inhibitor letrozole on ovulatory function in normal women. Fertil Steril 78:280.
- **Fluker M, Grifo J, Leader A, Levy M, Meldrum D, Muasher SJ, Rinehart J, Rosenwaks Z, Scott RT, Schoolcraft W, Shapiro DB,** North American Ganirelix Study Group. Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertil Steril **2001**; 75:38–45.
- **Fogelman I. (1992):**Gonadotropin-releasing hormone agonists and the skeleton. Fertil Steril; 57: 715-724.
- **Foresta C, Garolla A, Bartoloni L, Bettella A, Ferlin A.** Genetic abnormalities among severely oligospermic men who are candidates for intracytoplasmic sperm injection. J Clin Endocrinol Metab Jan;**2005** 90(1):152–156. [PubMed: 15509635].
- **Forman RG, Frydman R, Egan D, et al. (1990):** Severe ovarian hyperstimulation syndrome using gonadotropin-releasing hormone agonists for in vitro fertilization; a European series and a proposal for prevention. Fertil Steril; 53: 502-9.
- **Fotune J, Cushman R,wahl C, Kito S (2000):**{ The primordial to primary follicle transition}.Mol Cell Endocrinol 163(1-2):53-60. PMID10963874.
- **Franceschini I, Lomet D, Cateau M, Delsol G, Tillet Y, Caraty A (July 2006).** "Kisspeptin immunoreactive cells of the ovine preoptic area and arcuate nucleus co-express estrogen receptor alpha". Neurosci. Lett. 401 (3): 225–30. [doi:10.1016/j.neulet.2006.03.039](https://doi.org/10.1016/j.neulet.2006.03.039). PMID 16621281.
- **Fraser HM.(1988):**LHRH analogues: their clinical physiology and delivery systems.Bailliere's Clinical Obstetrics and Gynaecology ;2:639.

- **Friedman AJ, Barbieri RL, Doubilet PM, Fine C and Schiff I .(1990):** A randomized, double-blind trial of gonadotropin-releasing hormone agonist suppression. *Fertil Steril* 1990;52: 596-9.
- **Fujii S, Sagara M, Kudo H, et al (1997):** A prospective randomized comparison between long and discontinuous-long protocols of gonadotropin-releasing hormone agonist for in vitro fertilization. *Fertil Steril*:67: 1166-1168.
- **Gemzell CA (1962):** Induction of ovulation with human pituitary gonadotropins. *Fertil Steril* 13:153-168.
- **Germond M, Urner F, Chanson A, Primi MP, Wirthner D and Senn A (2004)** What is the most relevant standard of success in assisted reproduction?: the cumulated singleton/twin delivery rates per oocyte pick-up: the CUSIDERA and CUTWIDERA. *Hum Reprod* 19,2442-2444.
- **Gerris .L. De Vits A, Joostens M, et al, (1995):** Triggering of ovulation in human menopausal gonadotropin-stimulated cycle:, comparison between intravenously-administered gonadotropin-releasing hormone (100 and 500 micrograms). GnRH agonist (buserelin. 500 micrograms) and human chorionic gonadotropin (10.000 IU). *Hum. Reprod.* 10(1):56~62.
- **Gerris J, De Neubourg D, De Sutter P.** Cryopreservation as a tool to reduce multiple birth. *Reprod Biomed Online* **2003**;7:286–294.
- **Golan A, Ron EL R, Herman A, Soffer Y, et al (1989):** Ovarian hyperstimulation syndrome: an update review. *Obstet. gynecol. Surv.* 44:430.
- **Gomez-Palomares JL, Julia B, Acevedo-Martin B, Martinez-Burgos M, Hernandez ER and Ricciarelli E (2005)** Timing ovulation for intrauterine insemination with a GnRH antagonist. *Hum Reprod* 20,368-372.
- **Gonen Y, Dirnfeld M, Goldman S, et al (1991):** The use of long-acting gonadotropin-releasing hormone agonist (GnRH-a; decapeptyl) and gonadotropins versus short-acting GnRH-a (buserelin) and gonadotropins before and during ovarian stimulation for in vitro fertilization (IVF). *J In Vitro Fert Embryo Transf*;8:254-259.

References

- **Goswami SK, Das T, Chattopadhyay R, et al. (2004):** A randomized single-blind controlled trial of letrozole as a low-cost IVF protocol in women with poor ovarian response: a preliminary report. *Hum Reprod* 19:203 1 -5.
- **Gougeon A (1990):** In “establishing a successful human pregnancy, edited by RG. Edwards. Pp 49_62. Raven Press:NEW YORK.
- **Gougeon A (1996)** “Regulation of ovarian follicular development in primates: facts And hypotheses.” *Endocr Rev* 17 (2) 121_55. PMID 8706629.
- **Gougeon A (1986):** “dynamics of follicle growth in the human: a model from preliminary results” *Hum Reprod* 1 (2) 81-7. PMID 3558758.
- **Griesinger G, Dafopoulos K, Schultze-Mosgau A, Felberbaum R and Diedrich K (2004)** What is the most relevant standard of success in assisted reproduction? Is BESST (birth emphasizing a successful singleton at term) truly the best? *Hum Reprod* 19,1239-1241.
- **Griesinger G, Diedrich K, Devroey P and Kolibianakis EM (2005b)** GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis. *Hum Reprod Update* 12,159-168.
- **Griesinger G, Felberbaum R, Diedrich K:** GnRH antagonists in ovarian stimulation: a treatment regimen of clinicians' second choice? Data from the German national IVF registry. *Hum Reprod* 2005a, 20(9):2373-2375.
- **Griesinger G, Schultze-Mosgau A, Dafopoulos K, Schroeder A, Schroer A, von Otte S, Hornung D, Diedrich K and Felberbaum R (2005c)** Recombinant luteinizing hormone supplementation to recombinant follicle-stimulating hormone induced ovarian hyperstimulation in the GnRH-antagonist multiple-dose protocol. *Hum Reprod* 20, 1200–1206.
- **Griesinger G, Schultze-Mosgau A, Dafopoulos K, Schroeder A, Schroer A, von Otte S, Hornung D, Diedrich K and Felberbaum R (2005a)** Recombinant luteinizing hormone supplementation to recombinant follicle-stimulating hormone induced ovarian hyperstimulation in the GnRH-antagonist multiple-dose protocol. *Hum Reprod* 20,1200-1206.

- **Grochowski D, Kulikowsky M, Wolezynski S, kuezynski W and Szamatowia M (1997):**The outcome of in-vitro fertilization program in women with poly cystic ovary Syndrome. *Gynecol Endocrinol*; 11L 259-262.
- **Grunwald K, Rabe T, and Runnebaum.** Physiology of the menstrual cycle. In: *Manual on Assisted Reproduction*. Rabe, T., Diedrich, K., Strowitzki (eds). 2nd updated edit, Springer. New York. **2000**; PP23: 77.
- **Hamblen EC (1940):** Endocrine therapy of functional ovarian failure. *Am .J Obstet Gynecol* 40:615-662.
- **Hananel H, Robert C, Togas T. (2006):** A new era of ovulation induction; *Fertil Steril* 85:277. 2006.
- **Hansen M, Bower C, Milne E, de Klerk N, Kurinczuk JJ.** Assisted reproductive technologies and the risk of birth defects--a systematic review. *Hum Reprod* Feb;**2005** 20(2):328–338. [PubMed: 15567881].
- **Hansen M, Sullivan E, Jequier AM, et al.** Practitioner reporting of birth defects in children born following assisted reproductive technology: Does it still have a role in surveillance of birth defects? *Hum Reprod* **2007**;22(2):516–520. [PubMed: 17021189].
- **Hara T, Araki H, Kusaka M, Harada M, Cho N, Suzuki N, Furuya S and Fukino M (2003)** Suppression of a pituitary-ovarian axis by chronic oral administration of a novel nonpeptide gonadotropin-releasing hormone antagonist, TAK-013 in cynomolgus monkeys. *J Clin Endocrinol Metab* 88,1697-1704.
- **Heijnen EM, Macklon NS and Fauser BC (2004)** What is the most relevant standard of success in assisted reproduction? The next step to improving outcomes of IVF: consider the whole treatment. *Hum Reprod* 19,1936-1938.
- **Helenyse Mattanó, Renato Koike and Suzana de Fatima Paccola Mesquita. (2003)** Intracytoplasmic sperm injection procedure for infertility treatment in couples. *Acta Scientiarum. Health Sciences* Maringá, v. 25, no. 1, p. 1-5, 2003.
- **Henzl MR (1993):** Gonadotrophin-releasing hormone and analogues: from laboratory to bed side. *Clin Obstet Gynecol*;3606-635.

- **Henzl MR(1988):**Gonadotropin-releasing hormone (GnRH) agonists in the management of Endometriosis: A review. Clin Obstet Gynecol; 31: 840.
- **Herman J, Ron-El R and Golan A, et al. (1992):**Impaired corpus luteum function (g) and other undesired results of pregnancies associated with inadvertent administration of a long-acting agonist of gonadotropin-releasing hormone. Hum Reprod 1992; 7: 465-8.
- **HJoris1, Z.Nagy, H.Van de Velde, A.De Vos and A.Van Steirteghem (1998)** Intracytoplasmic sperm injection: laboratory set-up and injection procedure. European Society for Human Reproduction & Embryology Human Reproduction Volume 13 Supplement 1.
- **Hohmann FP, Laven JS, de Jong FH, Eijkemans MJ and Fauser BC (2001)** Low-dose exogenous FSH initiated during the early, mid or late follicular phase can induce multiple dominant follicle development. Hum Reprod 16,846-854.
- **Hohmann FP, Macklon NS and Fauser BC (2003)** A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol. J Clin Endocrinol Metab 88,166-173.
- **Holland F, Fishman L, Costigan DC, Luna L, Leeder S (1986):** pharmacokinetic characteristics of the gonadotropin releasing hormone analogue D-Ser (TBU)-6EA-10 luteinizing hormone-releasing hormone (buserelin) after subcutaneous and intranasal administration in children with central precocious puberty. J Clin Endocrinol Metab;63:1065-1070.
- **Homburg R, Levi T, Berkovitz D, et al (1993):** Gonadotropin releasing hormone agonist reduces the miscarriage rate for pregnancies achieved in women with poly cystic ovarian syndrome.Fertil Steril1993; 59:527-31.
- **Hughes E, Collins J and Vandekerckhove P (2000)** Clomiphene citrate for unexplained subfertility in women. Cochrane Database Syst Rev, CD000057.
- **Huirne JA, Lambalk CB, van Loenen AC, Schats R, Hompes PG, Fauser BC, Macklon NS.** Contemporary pharmacological manipulation in assisted reproduction. Drugs **2004**;64:297 – 322.

- **Humaidan P, Ejdrup Bredkjaer H, Bungum L, Bungum M, Grondahl ML, Westergaard L and Yding Andersen C (2005)** GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study. *Hum Reprod* 20,1213-1220.
- **Hurley DM, Brian R, Outch K, et al (1984):** Induction of ovulation and fertility in amenorrhoeic women by pulsatile low dose gonadotropin releasing hormone. *N Engl J Med* 1984;310:1069.
- **Hvidtjorn D, Grove J, Schendel DE, et al.** Cerebral palsy among children born after in vitro fertilization: the role of preterm delivery--a population-based, cohort study. *Pediatrics* Aug;2006 118 (2):475-482. [PubMed: 16882798].
- **Hwang JL, Huang LW, Hsieh BC, et al.** Ovarian stimulation by clomiphene citrate and HMG in combination with cetrorelix acetate for ICSI cycles. *Hum Reprod.* 2003;18: 45-49.
- **Hwang JL, Seow KM, Lin YH, Huang LW, Hsieh BC, Tsai YL, Wu GJ, Huang SC, Chen CY, Chen PH et al. (2004)** Ovarian stimulation by concomitant administration of cetrorelix acetate and HMG following Diane-35 pre-treatment for patients with polycystic ovary syndrome: a prospective randomized study. *Hum Reprod* 19,1993-2000.
- **Ingerslev HJ, Hojgaard A, Hindkjaer J, Kesmodel U (2001):** A randomized study comparing IVF in the unstimulated cycle with IVF following clomiphene citrate. *Hum Reprod* 16:696.
- **Insler V, Lunenfeld B.** Application of GnRH analogues in the treatment of female infertility. In: *GnRH Analogues The State of The Art*. Lunenfeld, B., Insler, V., (eds). Parthenon, New York. 1993;p: 37-48.
- **Jansen RPS, Handelsman DJ, Boylan LM, et al (1987):** Pulsatile intravenous gonadotropin releasing hormone for ovulation induction in infertile women. Safety and effectiveness with outpatient therapy. *Fertil Steril* 1987;48:33.
- **Jansens RM, Brus L, Cahill DJ, et al (2000a):** Direct ovarian effects and safety aspects of GnRH agonists and antagonists. *Hum Reprod Update*;6:505-518.

References

- **Jansens RM, Lambalk CB, Vermeiden JP, et al (2000b):** Dose-finding study of triptorelin acetate for prevention of a premature LH surge in IVF: a prospective, randomized, double-blind, placebo-controlled study. *Hum Reprod*; 15:2333-2340.
- **Johanssen JS, Riis BJ, Hassager C, et al.(1988):** The effects of a gonadotropin-releasing hormone agonist analog(nafarelin) on bone metabolism. *J Clin Endocrinol Metab* (1988) ;67: 701-6.
- **Johnson J, BagleyJ,Skaznik_wikiel M,et al. (2005)** Oocyte generation in adult mammalian ovaries by putative germ cells in bone marrow and peripheral blood. *Cell* 2005 Jul 29;122(2):303-15.
- **Johnson J, Canning J, Kaneko T, Pru J, Tilly .1 (2004):** "Germline stem cells and follicular renewal in the postnatal mammalian ovary.". *Nature* 428 (6979): 145-50. PMID 15014492.
- **Jones JS (1989):** Use of purified gonadotropins for ovarian stimulation in IVF, *New Clinical Issues in Vitro fertilization clinics .in Obstetrics and Gynecology* (12) 4. 775- 784.
- **Joseph P Alukal and Dolores J. Lamb 2008** Intracytoplasmic Sperm Injection (ICSI) – What are the risks? *Urol Clin North Am.* May ; 35(2): 277–288.
- **Kaiser UB, Corm IM, Chi WW,(1997):** Studies of GnRH action using GnRH receptor-expressing pituitary cell lines, *Endocr Rev* 18:46.
- **Karten M.J Rivier J.E (1986):** Gonadotropin-releasing hormone analog design, Structure-function studies toward the development of agonist and antagonists and antagonists: rationale and perspective *Endocr Rev.* 7: 44 - 46.
- **Keene JL, Matzuk. MM, Boime I (1989):** Expression of recombinant human choriogonadotropin in Chinese hamster ovary glycosylation mutants. *Mol Endocrinol* 3:2011-2017.
- **Kennedy, S.H., Williams, I.A., Brodribb, J. et al. (1990)** A comparison of nafarelin acetate and danazol in the treatment of endometriosis. *Human Reproduction Volume 11 Supplement 3* 1990.
- **Klein KO, Barnes KM, Jones IV, ct al (2001):.** Increased final height in precocious puberty after long-term treatment with LHRH agonists: the National Institutes of Health experience. *J Clin Endocrinol Mctab*;86:47114716.

- **Klingmuller D, Schepke M, Enzweiler C and Bidlingmaier F (1993)**
Hormonal responses to the new potent GnRH antagonist Cetrorelix. *Acta Endocrinol (Copenh)* 128,15-18.
- **Klip H, Burger CW, de KJ, van Leeuwen FE.** Risk of cancer in the offspring of women who underwent ovarian stimulation for IVF. *Hum Reprod* **2001**;16(11):2451–2458. [PubMed: 11679537].
- **Koivurova S, Hartikainen AL, Gissler M, Hemminki E, Sovio U, Jarvelin MR.** Neonatal outcome and congenital malformations in children born after in-vitro fertilization. *Hum Reprod* May; **2002** 17 (5):1391–1398. [PubMed: 11980770].
- **Koivurova S, Hartikainen AL, Sovio U, Gissler M, Hemminki E, Jarvelin MR.** Growth, psychomotor development and morbidity up to 3 years of age in children born after IVF. *Hum Reprod* Nov; **2003** 18(11):2328–2336. [PubMed: 14585883].
- **Kol S (2004)** Luteolysis induced by a gonadotropin-releasing hormone agonist is the key to prevention of ovarian hyperstimulation syndrome. *Fertil Steril* 81,1-5.
- **Kolibianakis E, Zikopoulos K, Camus M, Tournaye H, Van Steirteghem A and Devroey P (2004b)** Modified natural cycle for IVF does not offer a realistic chance of parenthood in poor responders with high day 3 FSH levels, as a last resort prior to oocyte donation. *Hum Reprod* 19,2545-2549.
- **Kolibianakis EM, Albano C, Camus M, Tournaye H, Van Steirteghem AC and Devroey P (2003a)** Initiation of gonadotropin-releasing hormone antagonist on day 1 as compared to day 6 of stimulation: effect on hormonal levels and follicular development in in vitro fertilization cycles. *J Clin Endocrinol Metab* 88,5632-5637.
- **Kolibianakis EM, Albano C, Camus M, Tournaye H, Van Steirteghem AC and Devroey P (2004a)** Prolongation of the follicular phase in in vitro fertilization results in a lower ongoing pregnancy rate in cycles stimulated with recombinant follicle-stimulating hormone and gonadotropin-releasing hormone antagonists. *Fertil Steril* 82,102-107.
- **Kolibianakis EM, Albano C, Kahn J, Camus M, Tournaye H, Van Steirteghem AC and Devroey P (2003b)** Exposure to high levels of luteinizing hormone and estradiol in the early follicular phase of gonadotropin-releasing hormone antagonist cycles is associated with a reduced chance of pregnancy. *Fertil Steril* 79,873-880.

- **Kolibianakis EM, Bourgain C, Platteau P, Albano C, Van Steirteghem AC and Devroey P (2003c)** Abnormal endometrial development occurs during the luteal phase of nonsupplemented donor cycles treated with recombinant follicle-stimulating hormone and gonadotropin-releasing hormone antagonists. *Fertil Steril* 80,464-466.
- **Kolibianakis EM, Collins J, Tarlatzis BC, Devroey P, Diedrich K, Griesinger G:** Among patients treated for IVF with gonadotrophins and GnRH analogues, is the probability of live birth dependent on the type of analogue used? A systematic review and meta-analysis. *Hum Reprod Update* **2006a**, 12(6):651-671.
- **Kolibianakis EM, Papanikolaou EG, Camus M, Tournaye H, Van Steirteghem AC, Devroey P. (2006b)** Oral contraceptive pill pretreatment on ongoing pregnancy rates in patients stimulated with GnRH antagonists and recombinant FSH for IVF. A randomized controlled trial. *Hum Reprod* 21:352–357.
- **Kolibianakis EM, Schultze-Mosgau A, Schroer A, van Steirteghem A, Devroey P, Diedrich K and Griesinger G (2005b)** A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists. *Hum Reprod* 20,2887-2892.
- **Kolibianakis EM, Tarlatzis BC and Devroey P (2005a)** GnRH antagonists in IVF. *Reprod Biomed Online* 10,705-712.
- **Kolibianakis EM, Zikopoulos K, Schiettecatte J, Smith J, Tournaye H, Camus M, Van Steirteghem AC and Devroey P (2004d)** Profound LH suppression after GnRH antagonist administration is associated with a significantly higher ongoing pregnancy rate in IVF. *Hum Reprod* 19,2490-2496.
- **Kolibianakis EM, Zikopoulos K, Smith J, Camus M, Tournaye H, Van Steirteghem AC and Devroey P (2004c)** Administration of gonadotropin-releasing hormone antagonist from day 1 of stimulation in in-vitro fertilization. *Fertil Steril* 82,223-226.
- **Kottler ML, Lorenzo F, Bergametti F, et al (1995):** Subregional mapping of the human gonadotropin-releasing hormone receptor (GnRH-R) gene to 4q between the markers D4S392 and D4S409. *Hum Genet*;96:477-480.

- **Kurzawa R, Ciepiela P, Baczkowski T, Safranow K, Brelik P:** Comparison of embryological and clinical outcome in GnRH antagonist vs. GnRH agonist protocols for in vitro fertilization in PCOS non-obese patients. A prospective randomized study. *Assist Reprod Genet* **2008**, 25(8):365-374.
- **Lanzone A, Guide M. Villa P, et al. (1994):** Gonadotropin-releasing hormone agonist versus human chorionic gonadotropin as a trigger of ovulation in polycystic ovarian disease gonadotropin hyperstimulation cycles, *fertil. Steril.* (62:35-40).
- **Laufer N. DeCherney AH, Haseltine FP. et al. (1983):** The use OF high dose human menopausal gonadotropin in an in vitro fertilization program. *Fertil Steril* 40:734-741.
- **Leiblum SR, Greenfield DA:** Infertility: psychological issues and counseling strategies. Edited by: Leiblum SR. New York: John Wiley & Sons; **1997**:83-102.
- **Lemay A, Brideau NA, Forest JC, ct al.(1991):**Cholesterol fractions and apolipoproteins during endometriosis treatment by a gonadotropin releasing hormone (GnRH) agonist implant or by danazol. *Clin Endocrinol (Oxf)* 1991; 35: 305-31.
- **Leroy I, dA' cremont MF, Barily-tabard S, Frydman R, de Mouzon J, Bouchard P.** A single injection of a gonadotropin-releasing hormone (GnRH) antagonist (Cetrorelix1) postpones the luteinizing hormone (LH) surge: further evidence for the role of GnRH during the LH surge. *Fertil Steril* **1994**; 62:461–7.
- **Lessy BA (2000):** Medical management of endometriosis and infertility. *Ferti Steril*: 73: 1089-1096.
- **Letterie GS, Stevenson D and Shag A.(1991):**Recurrent anaphylaxis to a depot form of GnRH analogue. *Obstet Gynecol* 1991; 78: 943.
- **Leunens L, Celestin-Westreich S, Bonduelle M, Liebaers I, Ponjaert-Kristoffersen I.** Cognitive and motor development of 8-year-old children born after ICSI compared to spontaneously conceived children. *Hum Reprod Nov*; **2006** 21(11):2922–2929. [PubMed: 16885388].
- **Lie RT, Lyngstadaas A, Orstavik KH, Bakketeig LS, Jacobsen G, Tanbo T.** Birth defects in children conceived by ICSI compared with children conceived by other IVF-methods; a meta-analysis. *Int J*

- Epidemiol Jun;2005 34(3):696–701. [PubMed: 15561745].
- **Lightman A, Jones EE and Boye's SP. (1991):** Ovulation induction: Human menopausal gonadotropins. Acta. Obst. gynecol. (Scand). 11 :88-92.
 - **Liu, J., Nagy, Z., Joris, H. et al. (1995)** Successful fertilization and establishment of pregnancies after intracytoplasmic sperm injection in patients with globozoospermia. Hum. Reprod., 10, 626-629.
 - **Lopata A (1983):** Concepts in human in vitro fertilization and embryo transfer. Fertil Steril 40:289-301.
 - **Loumaye E, Vankrieken L, Depreester S, et al (1999):** Hormonal changes induced by short-term administration of gonadotropin-releasing hormone agonist during ovarian hyperstimulation for in vitro fertilization and their consequences for embryo development. Fertil Steril;51:105-111.
 - **Loumaye E.** The control of endogenous secretion of LH by gonadotropin-releasing hormone agonists during ovarian hyperstimulation for in vitro fertilization and embryo transfer. Hum Reprod 1990; 5:357–76.
 - **Ludwig M, Katalinic A, Banz C, Schroder AK, Loning M, Weiss JM and Diedrich K (2002)** Tailoring the GnRH antagonist cetrorelix acetate to individual patients' needs in ovarian stimulation for IVF: results of a pro-spective, randomized study. Hum Reprod 17,2842-2845.
 - **Ludwig M, Katalinic A, Diedrich K:** Use of GnRH antagonists in ovarian stimulation for assisted reproductive technologies compared to the long protocol. Meta-analysis. Arch Gynecol Obstet 2001, 265(4):175-182.
 - **Ludwig M, Katalinic A, Gross S, Sutcliffe A, Varon R, Horsthemke B.** Increased prevalence of imprinting defects in patients with Angelman syndrome born to subfertile couples. J Med Genet 2005;42(4):289–291. [PubMed: 15805153].
 - **Ludwig M, Katalinic A.** Malformation rate in fetuses and children conceived after ICSI: results of a prospective cohort study. Reprod Biomed Online Sep-Oct;2002 5(2):171–178. [PubMed: 12419043].
 - **Lunenfeld B (2004):** Historical perspectives in gonadotropin the

- apy. Hum Reprod Update 10:453-467.
- **MacDougall M.I, Tan SL, Balen A. Jacobs US. (1993):** A controlled study comparing patients with and without polycystic ovaries undergoing in-vitro fertilization. Hum Reprod; 8:233-237.
 - **MacDougall MJ, Tan SL, and Jacobs HS.(1992):**In vitro fertilization and ovarian hyperstimulation syndrome. Hum Reprod 1992; 7: 597-600.
 - **Maduro MR, Casella R, Kim E, et al.** Microsatellite instability and defects in mismatch repair proteins:a new aetiology for Sertoli cell-only syndrome. Mol Hum Reprod Feb;2003 9(2):61–68. [PubMed:12569174].
 - **Maher ER.** Imprinting and assisted reproductive technology. Hum Mol Genet 2005;14(Spec No 1):R133–R138. [PubMed: 15809265].
 - **Matorras R. Rodriguez-Escudero FJ (2002):** The use of human gonadotrophins should be discouraged. Hum Reprod 17:1675.
 - **Matta WH, Shaw RW, Hesp R and Evans R(1988):**Reversible bone density loss following induced hypo-estrogenism with GnRH analogue Buserelin in premenopausal women. Clin Endocrinol 1988; 29: 45-51.
 - **Mau Kai C, Main KM, Andersen AN, Loft A, Skakkebaek NE, Juul A.** Reduced serum testosterone levels in infant boys conceived by intracytoplasmic sperm injection. J Clin Endocrinol Metab Jul; 2007 92(7):2598–2603. [PubMed: 17456568].
 - **Maudsley S, Davidson L, Pawson AJ, Chan R, Lopez de Maturana R and Millar RP (2004)** Gonadotropin-releasing hormone (GnRH) antagonists promote proapoptotic signalling in peripheral reproductive tumor cells by activating a G_{ai}-coupling state of the type I GnRH receptor. Cancer Res 64,7533-7544.
 - **McNatty KP, Makris AD, Gogruziac et al.** The production of progesterone, androgen and estrogen by granulosa cells. The cell tissue and stromal tissue from human ovaries in vitro. J. Clin Endocrinol Metab. 1979; 49: 687-99.
 - **Merviel P, Antoine JM, Mathieu E, Millot F, Mandelbaum J and Uzan S (2004)** Luteinizing hormone concentrations after gonadotropin-releasing hormone antagonist administration do not influence

- pregnancy rates in in vitro fertilization-embryo transfer. *Fertil Steril* 82,119-125.
- **Messinis IE, Loutradis D, Domali E, Kotsovassilis CP, Papastergiopoulou L, Kallitsaris A, Drakakis P, Dafopoulos K, Milingos S. (2005)** Alternate day and daily administration of GnRH antagonist may prevent premature luteinization to a similar extent during FSH treatment. *Hum Reprod* 20:3192–3197.
 - **Millar R, Lowe S, Conklin D, et al (2001):** A novel mammalian receptor for the evolutionarily conserved type II GnRH. *Proc Natl Acad Sci USA*;98:9636-9641.
 - **Millar RP, Lu Z, Pawson AJ, Flanagan CA, Morgan K and Maudsley SR (2004)** Gonadotropin-releasing hormone receptors. *Endocr Rev* 25,235-275.
 - **Min JK, Breheny SA, MacLachlan V and Healy DL (2004)** What is the most relevant standard of success in assisted reproduction? The singleton, term gestation, live birth rate per cycle initiated: the BESST endpoint for assisted reproduction. *Hum Reprod* 19,3-7. Mochtar MH (2004) The effect of an individualized GnRH antagonist protocol on folliculogenesis in IVF/ICSI. *Hum Reprod* 19,1713-1718.
 - **Mitwally M, .Casper R. (2002):** Aromatase inhibition for ovarian stimulation: future avenues for infertility management. *Curr Opin obstet .Gynecol..* 14:255-63. 2002.
 - **Mochtar MH (2004)** the effect of an individualized GnRH antagonist protocol on folliculogenesis in IVF/ICSI. *Hum Reprod* 19, 1713-171.
 - **Moll AC, Imhof SM, Cruysberg JR, Schouten-van Meeteren AY, Boers M, van Leeuwen FE.**Incidence of retinoblastoma in children born after in-vitro fertilisation. *Lancet* Jan 25;2003 361 (9354):309–310. [PubMed: 12559867].
 - **Molloy BG, Hancock KW and Glass MR (1985):** Ovulation induction in clomiphene nonresponsive patients the place of pulsatile gonadotropin releasing hormone in clinical practice. *Fertil Steril*; 43:26.
 - **Moraloglu O, Kilic S, Karayalcin R, Yuksel B, Tasdemir N, Isik A, Ugur M:** *Comparison of GnRH agonists and antagonists in normoresponder IVF/ICSI in Turkish female patients. Adv Ther* 2008, 25(3):266-273.

- **Morton et al., 2001:** "Medical statistics". In: *A study guide to epidemiology and biostatistics 5th ed.* By: Morton RF, Hebel JR and McCarter RJ. Aspen publication, Gaithersburg, Maryland, Pp: 71-74.
- **Muasher SJ, Abdallah RT, Hubayter ZR:** Optimal stimulation protocols for in vitro fertilization. *Fertil Steril* **2006**, 86(2):267-273.
- **Nagy, Z.P., Liu, J., Joris, H. et al (1995a)** The result of intracytoplasmic sperm injection is not related to any of the three basis sperm parameters. *Hum. Reprod.*, 10, 1123-1129.
- **Nagy, Z.P., Verheyen, G., Liu, J. et al. (1995b)** Results of 55 intracytoplasmic sperm injection cycles in the treatment of male-immunological infertility. *Hum. Reprod.*, 10, 1775-1780.
- **Neil JD, Duck LW, Seller JC, Musgrove LC. (2001):** A gonadotropin releasing hormone (GnRH) receptor specific for GnRH II in primates. *Biochem Biophys Res Commun*;282:1012-1018.
- **Nencioi T, Penotti M, and Barbieri-Carones M etal (1991):** GnRH agonist therapy and its effect on bone mass. *Gynecol Endocrinol* ;5:49-56.
- **Ng EH, Chui DK, Tang OS, Lau EV, Yeung WS, Chung HP (2001):** In vitro fertilization and embryo transfer during natural cycles. *J Reprod Med* 46:95.
- **Nikolettos A simlakopoulos B, Diedrich K, et al .** Triptorelin versus cetorelix in intracytoplasmic sperm injection cycles in women with a single ovary. *Eur. J. Obstet. Gynecol Reprod Biol.* **2004**; 112 (2): 185-8.
- **Olivennes F, Alvarez S, Bouchard P, Fanchin R, Salat-Baroux J and Frydman R (1998)** The use of a GnRH antagonist (Cetorelix) in a single dose protocol in IVF-embryo transfer: a dose finding study of 3 versus 2 mg. *Hum Reprod* 13,2411-2414.
- **Olivennes F, Belaisch-Allart J, Emperaire JC, Dechaud H, Alvarez S, Moreau L, Nicollet B, Zorn JR, Bouchard P, Frydman R:** Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetorelix) or a depot formula of an LH-RH agonist (triptorelin). *Fertil Steril* **2000**,

73(2):314-320.

- **Olivennes F, Fanchin R, Bouchard P, de Ziegler D, Taieb J, Selva J and Frydman R (1994)** The single or dual administration of the gonadotropin releasing hormone antagonist Cetrorelix in an in vitro fertilization-embryo transfer program. *Fertil Steril* 62,468-476.
- **Olivennes F, Fanchin R, Bouchard P, Taieb J, Selva J, Frydman R:**Scheduled administration of a gonadotrophin-releasing hormone antagonist (Cetrorelix) on day 8 of in-vitro fertilization cycles: a pilot study. *Hum Reprod* **1995**, 10(6):1382-1386.
- **Ombelet W, De Sutter P, Van der Elst J, Martens G.** Multiple gestation and infertility treatment: registration, reflection and reaction—the Belgian project. *Hum Reprod Update* **2005**;11:3–4.
- **Oppenheim DS, Bikkal H, Crowley WF Jr, Klibanski A (1992):** Effects of chronic GnRH analogue administration on gonadotrophin and alpha-subunit secretion in postmenopausal women. *Clin Endocrinol (Oxf)*;36:559-564.
- **Out HJ, Rutherford A, Fleming R, Tay CC, Trew G, Ledger W and Cahill D (2004)** A randomized, double-blind, multicentre clinical trial comparing starting doses of 150 and 200 IU of recombinant FSH in women treated with the GnRH antagonist ganirelix for assisted reproduction. *Hum Reprod* 19,90-95.
- **Palermo G, Joris H, Devroey P, Van Steirteghem AC.** Pregnancies after intracytoplasmic injection of single spermatozoon into an oocyte. *Lancet* **1992**;340:17–18.
- **Papanikolaou EG, Kolibianakis E and Devroey P (2005)** Emerging drugs in assisted reproduction. *Expert Opin Emerg Drugs* 10,425-440.
- **Pellestor F, Dufour MC, Arnal F, Humeau C.** Direct assessment of the rate of chromosomal abnormalities in grade IV human embryos produced by in-vitro fertilization procedure. *Hum Reprod* Feb;**1994** 9(2):293–302. [PubMed: 8027286].
- **Pinborg A, Lidegaard O, la Cour Freiesleben N, Andersen AN.** Vanishing twins: a predictor of small- for-gestational age in IVF singletons. *Hum Reprod* Oct;**2007** 22(10):2707–2714. [PubMed: 17728356].

- **Pinborg A, Loft A, Nyboe AA.** Neonatal outcome in a Danish national cohort of 8602 children born after in vitro fertilization or intracytoplasmic sperm injection: the role of twin pregnancy. *Acta Obstet Gynecol Scand* **2004**;83(11):1071–1078. [PubMed: 15488125].
- **Pinborg A.** IVF/ICSI twin pregnancies: risks and prevention. *Hum Reprod Update* **2005**;11(6):575– 593. [PubMed: 16123055].
- **Ponjaert-Kristoffersen I, Bonduelle M, Barnes J, et al.** International collaborative study of intracytoplasmic sperm injection-conceived, in vitro fertilization-conceived, and naturally conceived 5-year-old child outcomes: cognitive and motor assessments. *Pediatrics* Mar;**2005** 115(3):e283–289. [PubMed: 15741353].
- **Porcu E, Fabbri R, Marsella T, Primavera M.R, Seracchioli R, Ciotti P.M, Magrini O, Venturoli S and Flamigni C.(1994)** Cryopreservation, *Hum. Reprod.*, December 1998; 13: 98 - 108.
- **Porcu E, Filicori M, Dal Prato L, et al (1995):** Comparison between depot leuporelin and daily buserelin in IVF. *J Assist Reprod Genet*; 12:15-19.
- **Porter RN, Smith W, Craft IL, Abdulwahid NA and Jacobs HS (1984)** Induction of ovulation for in-vitro fertilisation using buserelin and gonadotropins. *Lancet* 2,1284-1285.
- **Probst JC, Skutella T, Muller-Schmid A, et al (1995):** Molecular and cellular analysis of rPl.B in the rat hypothalamus: in situ hybridization and immunohistochemistry of a new P-domain neuropeptide. *Brain Res Mol Brain Res*;33:269-276.
- **Rabe T, Diedrich K and Strowitzki T (2002):** Manual on Assisted Reproduction (3rd ed.) In: Klawns Grunwald, Gthomas Rabe and Bule Runnebaum; Eds. *Physiology of the menstrual cycle*. Lippincotte Reven; pp 23-66.
- **Ragni G, Alagna F, Brigante C, Riccaboni A, Colombo M, Somigliana E and Crosignani PG (2004)** GnRH antagonists and mild ovarian stimulation for intrauterine insemination: a randomized study comparing different gona-dotropin dosages. *Hum Reprod* 19,54-58.
- **Ragni G, Vegetti W, Baroni E, Colombo M, Arnoldi M, Lombroso G**

- and Crosignani PG (2001)** Comparison of luteal phase profile in gonadotropin stimulated cycles with or without a gonadotropin-releasing hormone antagonist. *Hum Reprod* 16,2258-2262.
- **Reissman T, Felberbaum R, Diedrich K, Engel J, Comaru-Schally AM, Schally AV.** Development and applications of luteinizing hormone-releasing hormone agonists in the treatment of infertility: an overview. *Hum Reprod* **1995**; 10:1974–81.
 - **Riis BJ, Christiansen C, Johansen JS and Jacobsen J. (1990):**Is it possible to prevent bone loss in young women treated with luteinizing hormone releasing-hormone agonists? *J. Clin. Endocrinol. Metab*; 70: 699-705.
 - **Rombauts L, Healy D, Norman RJ. On behalf of the Orgalutran Scheduling Study Group. (2006)** A comparative randomized trial to assess the impact of oral contraceptive pretreatment on follicular growth and hormone profiles in GnRH antagonist-treated patients. *Hum Reprod* 21:95–103.
 - **Rongieres-Bertrand C, Olivennes F, Righini C, Fanchin R, Taieb J, Hamamah S, Bouchard P and Frydman R (1999)** Revival of the natural cycles in in-vitro fertilization with the use of a new gonadotrophin-releasing hormone antagonist (Cetrorelix): a pilot study with minimal stimulation. *Hum Reprod* 14,683-688.
 - **Roulier R, Chabert-Orsini V, Sitri MC, Barry B, Terriou P.** Depot GnRH agonist versus the single dose GnRH antagonist regimen (cetrorelix, 3 mg) in patients undergoing assisted reproduction treatment. *Reprod Biomed Online* **2003**;7:185–9.
 - **Sallam HN.** Physiology of reproduction. In: Infertility and Assisted Conception. ^{2nd} edit . Salam, H,N,
 - **Schally AV, Nair RM, Redding TW, Arimura A (1971):** Isolation of the luteinizing hormone and follicle-stimulating hormone-releasing hormone from porcine hypothalamus. *J Bio Chem*;246:7230-7236.
 - **Scharla Sh, Minne HW , Waibel-treber S, et al. (1990):**Bone mass reduction after estrogen deprivation by long-acting gonadotropin releasing hormone agonists and its relation to pretreatment serum concentration of 1,25-dihydroxyvitamin D3, *J. Clin. Endocrinol. Metab*; 70: 1055-1061.
 - **Schmidt GE, Kin MH, Mansour R, Torello L. Friedman CI:**

- (1986): The effects of enclomiphene and zuclophene citrates on mouse embryos fertilized in vitro and in vivo. *Am J Obstet Gynecol* 154:727.
- **Sealfon SC, Weinstein H and Millar RP (1997):** Molecular mechanism of ligand interaction with the gonadotropin releasing hormone receptor. *Endocrinol. Rev*; 18: 180-205.
 - **Shaked GM, Shaked Y, Kariv-Inbal Z, Halimi M, Avraham I, Gabizon R (2001):** A protease-resistant prion protein isoform is present in urine of animals and humans affected with prion diseases. *J Biol Chem* 276:31479-31482.
 - **Shoham (Shwartz) Z, Borenstein R, Lunenfeld B, et al. (1999):** hormonal profiles following clomiphene citrate therapy in conception and non conception cycles. *Clin. Endocrinol (oxf)*: 33:271-278.
 - **Shoham Z and Insler V (1996):** Recombinant technique and gonadotropins production: new era in reproductive medicine. *Fertil Steril*; 66 : 187-201.
 - **Shoham Z, Homburg R, Jacobs HS. (1990):** Induction of ovulation with pulsatile GnRH. *Baillieres Clin Obstet Gynaecol*;4:589-608.
 - **Shoham Z, Schacter M, Loumaye E, Weissman A, MacNamee M, Insler V (1995):** The luteinizing hormone surge-the final stage in ovulation induction: modern aspects of ovulation triggering. *Fertil Steril* 64:237-251.
 - **Shozu M, Sebastian S, Takayama K, et al. (2003):** Estrogen excess associated with novel gain-of-function mutations affecting the aromatase gene. *N Engl J Med* 348: 1855-65.
 - **Simpson JL, Lamb DJ.** Genetic effects of intracytoplasmic sperm injection. *Semin Reprod Med* **2001**;19(3):239–249. [PubMed: 11679905].
 - **Smitz J, Erard P, Camus M, et al. (1992):** Pituitary gonadotrophin secretory capacity during the luteal phase in superovulation using GnRH-agonists and HMG in a desensitization or flare-up protocol. *Hum Reprod* 7:1225,1229.
 - **Smitz J, Camus M, Devroey P, et al (1991):** The influence of inadvertent intranasal buserelin administration in early pregnancy. *Hum Reprod* ; 6: 290-293.

- **Speroff L, Fritz M. (2005):** Induction of ovulation In: Speroff L. Fritz M (eds.) Vol. II Clinical Gynecologic Endocrinology & infertility. Williams & Wilkins Bathmore. London pp 1175-1214.
- **Speroff L, Glass RH, Kase NG:** Clinical Gynecologic Endocrinology and Infertility, 6th ed, pp 534–535. Baltimore, Lippincott Williams & Wilkins, 1999.
- **Spitz M, Chertin B, Lindenberg T, Farkas A (1999):** Long acting gonadotropin releasing hormone implant to maintain medical castration for two years in men with prostat cancer [letter]. N Engl J Med;340:1439.
- **Steinkampf MP, Krotzer P., McElory F. et al (1992):** A simplified approach to invitro fertilization. .J. Reprod. Med... 37: 199-204.
- **Stephoe PC, Edwards RG.** Birth after the reimplantation of a human embryo. Lancet Aug 12;1978 2 (8085):366. [PubMed: 79723].
- **Stojikovic SS, Reinhart J, Cart KJ (1994):** Gonadotropin releasing hormone receptors: structure and signal transduction pathways. Endor Rev; 15:462-499.
- **Stromberg B, Dahlquist G, Ericson A, Finnstrom O, Koster M, Stjernqvist K.** Neurological sequelae in children born after in-vitro fertilisation: a population-based study. Lancet Feb 9;2002 359(9305): 461–465. [PubMed: 11853790].
- **Syntex (Synarel). (1992):**Physicians Desk Reference. Montvale, NJ, Medical Economics Data, 1992,p 2300.
- **Szontagh FE (1983):** Short-loop (internal) pituitary- hypothalamus gonadotroph feedback in the human. Endocrinol Exp; 7:65.New York. 2002; P:3-41.
- **Tan SL, Kingsland C ,Campbell S , et al. (1992):**The long protocol of C&D administration of gonadotropin-releasing hormone agonist is superior to the short protocol for ovarian stimulation for in vitro fertilization. Fertil Steril 1992; 57: 810-814.
- **Tanbo T, Dale PO, Kjeksjus E and Abyholm T. (1990):**Stiniulation with human menopausal gonadptropins versus follicle-stimulating

- hormone after pituitary suppression in polycystic ovarian syndrome *Fertil Steril*; 53: 798-803.
- **TAP PharmaceuticalLupron (1992)** 22 Aug 1999 ... Hamelburg, 59. www.endocenter.org/pdf/gnrhwitharticles.pdf.
 - **Tarlatzis BC and Grimbizis G (2002)**: GnRH-agonist. In: Ovulation induction; 12 : 157-170.
 - **Tarlatzis BC and Crimbizis G (1997)**: Gonadotrophin releasing hormone agonists in controlled ovarian hyperstimulation. *Ref Gynecol Obstet*: 5 : 180-190.
 - **Tarlatzis BC and Kolibianakis EM (2002)** Direct ovarian effects and safety aspects of GnRH agonists and antagonists. *Reprod Biomed Online* 5,8-13.
 - **Tarlatzis BC, Bili H, Bontis J, Lagos S, Vatev I and Mantalenakis S (1994)**: Follicle cyst formation after administration of different GnRH analogues for assisted reproduction. *Hum Reprod*; 9: 1983-1986.
 - **Tarlatzis BC, Fauser BC , Kolibianakis EM, Diedrich K and Devroey P. (2006)**"GnRH antagonists in ovarian stimulation for IVF." *Human Reproduction Update*, 12 No.4 : 333–340.
 - **Taymor ML. (1996)**: The regulation of follicle growth.: Some clinical implications in reproductive endocrinology. *So: Fertil. Steril*: 62(2): 235-247.
 - **Templeton A, Morris JK.** Reducing the risk of multiple births by transfer of two embryos after in vitro fertilization. *N Engl J Med* **1998**;339: 573–577.
 - **The European and Middle East Orgalutran Study Group**: Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. *Hum Reprod* **2001**, 16(4):644-651.
 - **The European Orgalutran Study Group, Borm G, Mannaerts B**:Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. *Hum Reprod* **2000**,15(7):1490-1498.

- **The Ganirelix Dose-Finding Study Group (1998)** A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotropin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). *Hum Reprod* 13,3023-3031.
- **The North American Ganirelix Study Group, Fluker M, Grifo J, Leader A, Nicollet B, Levy M, Meldrum D, Muasher SJ, Rinehart J, Rosenwaks Z, Scott RT Jr, Schoolcraft W, Shapiro DB:** Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. *Fertil Steril* 2001, 75(1):38-45.
- **Thibault, c., and LEVASSEUR. MC. (1988):** *Hum. Reprod.*, 3:513_523.
- **Thurin A, Hausken J, Hillensjo T, et al.** Elective single-embryo transfer versus double-embryo transfer in in vitro fertilization. *N Engl J Med* Dec 2;2004 351(23):2392–2402. [PubMed: 15575055.
- **Tiitinen A, Hyden-Granskog C and Gissler M (2004)** What is the most relevant standard of success in assisted reproduction?: the value of cryopreservation on cumulative pregnancy rates per single oocyte retrieval should not be forgotten. *Hum Reprod* 19,2439-2441.
- **Tummon IS, Ali A , Pepping ME, et al. (1988):** Bone mineral density in women with endometriosis before and during ovarian suppression with gonadotropin releasing hormone agonists of danazol. *Fertil Steril* 1988; 49: 792-6.
- **Uemura T, Mohri J, Osada H, et al. (1994):**Effect of gonadotropin-releasing hormone agonist on the bone mineral density of parents with endometriosis *Fertil Steril*; 62: 246-250.
- **Van Landuyt L, Verheyen G, Tournaye H, Camus M, Devroey P, Van Steirteghem A.** New Belgian embryo transfer policy leads to sharp decrease in multiple pregnancy rate. *Reprod Biomed Online* 2006;13:765–771.
- **Van Balen F, Verdurmen J, Ketting E:** Choices and motivations of infertile couples. *Patient Educ Counsl* 1997, 31:19-2.

- **Van de Weijer BH, Mulders JW, Bos ES. et al. (2003):** Coimpositional analyses of a human menopausal gonadotrophin preparation extracted from urine (menotropin). Identification of some of its major impurities. *Reprod Biomed Online* 7:547.
- **Van den Hurk R,Zhao J (2005):** “Fofmation of oocytes and their growth differentiation and maturation within overian follicles.” *Theriology* 63 (6): 1717_51. PMID 15763114.
- **Van Heusden AM and Fauser BC (2002)** Residual ovarian activity during oral steroid contraception. *Hum Reprod Update* 8,345-358.
- **Van Loenen ACD, Huirne JAF, Schats R, Donnez J and Lambalk CB (2001)** An open-label multicentre, randomized, parallel, controlled phase II study to assess the feasibility of a new programming regimen using an oral contraceptive prior to the administration of recombinant FSH and a GnRH-antagonist in patients undergoing ART (IVF-ICSI) treatment. *Hum Reprod* 16,144.
- **Van Steirteghem, A.C., Nagy, Z., Joris, H. et al. (1993)** High fertilization and implantation rates after intracytoplasmic sperm injection. *Hum. Reprod.*, 8, 1061-1066.
- **Varney NR, Syrop C, Kubu CS, Struchen M, Hahn S and Franzen K (1993)** Neuropsychologic dysfunction in women following leuprolide acetate induction of hypoerogenism. *J Assist Reprod Genet* 10,53-57.
- **Velasco G, Isaza V, Vidad C, et al .** Human ovarian steroid secretion in vivo: effects of GnRH agonist versus antagonist (cetorelix). *Hum Reprod.* **2001**; 16 (12): 2533-9.
- **Vlaisavljevic V, Lovrec VG and Kovacic B (2003)** Comparable effectiveness using flexible single-dose GnRH antagonist (cetorelix) and single-dose long GnRH agonist (goserelin) protocol for IVF cycles - a prospective, randomized study. *Reprod Biomed Online* 7,301-308.
- **Wada I, Matson PL. Troup SA and Lieberman BA. (1993)** Assicted conception using buserelin and human menopausal gonadotropins in women with polycystic . ovary syndrome. *Br J Obstet Gynecol*; 100: 265-9.

- **Wang YA, Dean J, Grayson N, Sullivan EA.** Assisted reproduction technology in Australia and New Zealand 2004. Australian Institute of Health and Welfare, National Perinatal Statistical Unit and the Fertility Society of Australia. Assisted Reproductive Technology Series, Number 10, November, **2006**. www.npsu.unsw.edu.au.
- **Wang YA, Dean J, Sullivan EA.** Assisted reproduction technology in Australia and New Zealand 2005. Australian Institute of Health and Welfare, National Perinatal Statistical Unit and the Fertility Society of Australia. Assisted Reproductive Technology Series, Number 11, September, **2007**. www.npsu.unsw.edu.au.
- **Ward HJT, Balen A and Will RG (2004)** Creutzfeld–Jakob disease and urinary gonadotrophins. Hum Reprod 19,in press.
- **Weiss JM, Oltmanns K, Gurke EM, Polack S, Eick F, Felberbaum R, Diedrich K and Ortmann O (2001)** Actions of gonadotropin-releasing hormone antagonists on steroidogenesis in human granulosa lutein cells. Eur J Endocrinol 144,677-685.
- **Weissman A and Shoham Z (1999):** GnRH and its agonists; basic knowledge. In Shoham Z, Howies CM and Jacobs HS (eds). Martin DunitzLtd publisher. Female infertility therapy ; 14: 159.
- **Westergaard LG, Erb K, Laursen SB, et al (2001):** Human menopausal gonadotropin versus recombinant follicle-stimulating hormone in normogonadotropic women down-regulated with a gonadotropin-releasing hormone; agonist who. were undergoing in vitro fertilization and intracytoplasmic sperm injection: a prospective randomized study. Fertil Steril;76:543-549.
- **Westergaard LG, Laursen SB and Andersen CY (2000)** Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in normogonadotropic women undergoing assisted reproduction. Hum Reprod 15,1003-1008.
- **White RB, Eiscn JA, Kastcn TL, Fernald RD, (1998):** Second gene for gonadotropin-releasing hormone in humans. Proc Natl Aoad Sci USA;95-305-309.
- **Wikland M, Bergh C, Borg K, Hillensjo T, Howles CM, Knutsson A,**

- Nilsson L and Wood M (2001)** A prospective, randomized comparison of two start-ing doses of recombinant FSH in combination with cetrorelix in women undergoing ovarian stimulation for IVF/ICSI. *Hum Reprod* 16,1676-1681.
- **Wilcox J, Potter D, Moore M, Ferrande L, Kelly E:** Prospective, randomized trial comparing cetrorelix acetate and ganirelix acetate in a programmed, flexible protocol for premature luteinizing hormone surge prevention in assisted reproductive technologies. *Fertil Steril* **2005**, 84(1):108-117.
 - **Wildt L, Hausler A and Marshall G.(1981):**Frequency and amplitude of gonadotropin-releasing hormone stimulation and gonadotropin secretion in the rhesus monkey. *Endocrinology* 1981; 109: 376.
 - **Wong JM, Forrest KA, Snabes SZ, et al (2001):** Efficacy of nafarelin in assisted reproductive technology: a meta-analysis. *Hum Reprod Update*;7: 92-101.
 - **Wright VC, Chang J, Jeng G, Chen M, Macaluso M,** Assisted Reproductive Technology Surveillance, United States (2004). *MMWR Surveill Summ* **2007**; 56(ss-6):1–12.
 - **Wright VC, Chang J, Jeng G, Macaluso M.** Assisted reproductive technology surveillance—United States, 2003. *MMWR Surveill Summ* **2006**;55(4):1–22. [PubMed: 16723970].
 - **Wright VC, Schieve LA, Reynolds MA, Jeng G.** Assisted reproductive technology surveillance-- United States, 2002. *MMWR Surveill Summ Jun 3*;2005 54(2):1–24. [PubMed: 1593115.
 - **Yahalom D, Chen A, Ben Aroya N, et al. (1999):** The gonadotropin-releasing hormone family of neuropeptides in the brain of human, bovine and rat: identification of a third isoform. *FEBS Lett*;463:289-294.
 - **Yang-Feng TL, Seeburg PH Francke U. (1986):** Human luteinizing hormone-releasing hormone gene (LHRH) is located on short arm of chromosome 8 (region 8p11.2-p21). *SomatCell Mol Genet*;12:95-100.
 - **Zadori J, Kozinszky Z, Orvos H, Katona M, Pal A, Kovacs L.** Dilemma of increased obstetric risk in pregnancies following IVF-ET. *J Assist Reprod Genet Jun*;2003 20(6):216–221. [PubMed: 12877252].

References

- ***Zeilmaker GH, Alberda AT, Van Gent I, Rijkmans CM, Drogendijk AC.*** Two pregnancies following transfer of intact frozen thawed embryos. *Fertil Steril* **1984**;42:293 – 296.
- ***Zhu JL, Basso O, Obel C, Bille C, Olsen J.*** Infertility, infertility treatment, and congenital malformations: Danish national birth cohort. *BMJ* **2006**;333(7570):679. [PubMed: 16893903].